Search

Your search keyword '"Philippe Rochigneux"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Philippe Rochigneux" Remove constraint Author: "Philippe Rochigneux" Topic business.industry Remove constraint Topic: business.industry
26 results on '"Philippe Rochigneux"'

Search Results

1. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

2. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome

Catalog

Books, media, physical & digital resources

3. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma

4. Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

5. Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion

6. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology

7. Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

8. Les glycosylations de PD-L1 sous les feux de la rampe

9. Acute myositis

10. Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study

11. Mortality of Patients with Cancer Presenting with Symptoms of COVID-19 With vs Without Detectable SARS-CoV-2: A Nationwide Prospective Cohort Study

12. Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma

13. Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review

14. Are lung adenocarcinoma mutations shaping the immune microenvironment?

15. Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC)

16. Does radical surgery for gastric cancer after 70 years prolong survival?

17. Hospital end-of-life care in haematological malignancies

18. P1.04-33 Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001

19. Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors

20. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

21. Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study

22. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review

23. Use of chemotherapy near the end of life: what factors matter?

24. End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study

25. Use of chemotherapy near the end of life for solid cancers: What factors matter?

26. Burden of inpatient care and treatments in terminally-ill cancer patients: results from a population-based, retrospective study from administrative data in France